PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24356814-7	2014	In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED)(70) = 11.2 mg/kg].	ralimetinib	87-96	MAPK activated protein kinase 2	Homo sapiens	58-61	
24356814-7	2014	In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED)(70) = 11.2 mg/kg].	ralimetinib	87-96	MAPK activated protein kinase 2	Homo sapiens	65-68	
23335506-7	2013	LY2228820 dimesylate results were substantiated using p38alpha MAPK-specific shRNA and shRNA against the downstream p38 MAPK effectors MAPKAPK-2 and HSP27.	ralimetinib	0-9	MAPK activated protein kinase 2	Homo sapiens	135-144